From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Event | No. of patients (%) |
---|---|
Constipation | 12 (13.5) |
Local reaction | 2 (2.2) |
Pruritus | 2 (2.2) |
Flu-like symptoms | 2 (2.2) |
Abdominal cramps | 1 (1.1) |
Transient skin rash | 1 (1.1) |
Bloating | 1 (1.1) |
Meteorism | 1 (1.1) |
Nausea | 1 (1.1) |
Transient vaginal spotting | 1 (1.1) |
Urticariaa | 1 (1.1) |
Vertigo | 1 (1.1) |
Allergic reactionb | 1 (1.1) |
Serious adverse events | 1 (1.1) |
Adverse events leading to treatment discontinuation | 1 (1.1) |
Total | 20 (22.5) |